EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Fungal lung disease

Tavleen Kaur Jaggi, Ritesh Agarwal, Pei Yee Tiew, Anand Shah iD, Emily C Lydon, Chadi A Hage, Grant W Waterer, Charles R Langelier, Laurence Delhaes iD, Sanjay H Chotirmall iD

European Respiratory Journal · 2024-11 · 64 (5) · 2400803

DOI: 10.1183/13993003.00803-2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 03.10.2024. Verfasst von Tavleen Kaur Jaggi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. Hauptthemen laut MEDLINE: Antifungal Agents, Lung Diseases, Fungal, Aspergillus. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 285 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, Ministry of Education - Singapore, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fungal lung disease encompasses a wide spectrum of organisms and associated clinical conditions, presenting a significant global health challenge. The type and severity of disease are determined by underlying host immunity and infecting fungal strain. The most common group of diseases are associated with the filamentous fungus Aspergillus species and include allergic bronchopulmonary aspergillosis, sensitisation, aspergilloma and chronic and invasive pulmonary aspergillosis. Fungal lung disease remains epidemiologically heterogenous and is influenced by geography, environment and host comorbidities. Diagnostic modalities continue to evolve and now include novel molecular assays and biomarkers; however, persisting challenges include achieving rapid and accurate diagnosis, particularly in resource-limited settings, and in differentiating fungal infection from other pulmonary conditions. Treatment strategies for fungal lung diseases rely mainly on antifungal agents but the emergence of drug-resistant strains poses a substantial global threat and adds complexity to existing therapeutic challenges. Emerging antifungal agents and increasing insight into the lung mycobiome may offer fresh and personalised approaches to diagnosis and treatment. Innovative methodologies are required to mitigate drug resistance and the adverse effects of treatment. This state-of-the-art review describes the current landscape of fungal lung disease, highlighting key clinical insights, current challenges and emerging approaches for its diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsLung Diseases, FungalAspergillusHumansDrug Resistance, FungalAspergillosis, Allergic BronchopulmonaryInvasive Pulmonary AspergillosisPulmonary Aspergillosis

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore.
  • Duke-NUS Medical School, Singapore, Singapore.
  • Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • MRC Centre of Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.

ORCID-Profile: Anand Shah, Laurence Delhaes, Sanjay H Chotirmall

Förderung

  • NIAID NIH HHS
  • Ministry of Education - Singapore
  • National Medical Research Council

Zitieren

APA

Jaggi, T. K., Agarwal, R., Tiew, P. Y., Shah, A., Lydon, E. C., Hage, C. A., Waterer, G. W., Langelier, C. R., Delhaes, L., & Chotirmall, S. H. (2024). Fungal lung disease. European Respiratory Journal, 64(5), 2400803. https://doi.org/10.1183/13993003.00803-2024

Vancouver

Jaggi TK, Agarwal R, Tiew PY, Shah A, Lydon EC, Hage CA, et al. Fungal lung disease. European Respiratory Journal. 2024;64(5):2400803. doi:10.1183/13993003.00803-2024

BibTeX
@article{Jaggi2024,
  author = {Jaggi, Tavleen Kaur and Agarwal, Ritesh and Tiew, Pei Yee and Shah, Anand and Lydon, Emily C and Hage, Chadi A and Waterer, Grant W and Langelier, Charles R and Delhaes, Laurence and Chotirmall, Sanjay H},
  title = {Fungal lung disease},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {64},
  number = {5},
  pages = {2400803},
  doi = {10.1183/13993003.00803-2024}
}
Kostenlos starten →